SEC filing record
Primary Source · SEC.gov

IMMUNIC, INC.

2026 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2026-03-043 events: 2 new form d filer, 1 large raiseLast filing 2026-03-04

Raised

$200M

Investors

43

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

IMMUNIC, INC. is a Delaware corporation that first filed a Form D on February 17, 2012 and most recently amended it on March 4, 2026 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. IMMUNIC, INC. reported $200,000,000 sold from 43 investors of a $200,000,000 total offering as of the Form D filed March 4, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Leerink Partners LLC (CRD 000039011), associated with None; STIFEL, NICOLAUS & COMPANY, INCORPORATED (CRD 000000793), associated with None; GUGGENHEIM SECURITIES, LLC (CRD 000040638), associated with None; WILLIAM BLAIR & COMPANY, LLC (CRD 000001252), associated with None and 3 others as recipients of sales compensation soliciting in CA, CO, CT, DE, GA, IL, MA, NC, NY, TX. Sales commissions are reported as $12,000,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 1200 Avenue of the Americas, Suite 200, New York, United States 10036.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001280776
Entity NameIMMUNIC, INC.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address1200 Avenue of the Americas, Suite 200, New York, United States 10036
Phone(332) 255-9818
Former NamesVITAL THERAPIES INC (until April 10, 2019)
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateFebruary 17, 2026
Filing DateMarch 4, 2026
Accession Number0001193805-26-000217
Total Offering Amount$200,000,000
Total Amount Sold$200,000,000
Amount Remaining$0
Total Investors43
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$12,000,000 (to Leerink Partners LLC and 6 others)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)X1
Amendment Count7 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

3

latest Mar 4, 2026

Critical / warning

0 / 0

3 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

3

closed, dark

Latest event New filer · Mar 4, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 3 filing events with values and deltas, latest 2026-03-04, and alerts on the next one
  • 3 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2026-03-04: 4 related persons added and 2 removed against the filing of 2024-01-19; 14 now listed. The names are in the Terminal feed.

DANIEL VITT

Executive Officer, Director · New York, NY

SIMONA SKERJANEC

Director · NEW YORK, NY

DUANE NASH

Director · New York, NY

TAMAR HOWSON

Director · New York, NY

JOERG NEERMAN

Director · New York, NY

RICHARD RUDICK

Director · New York, NY

ANDREAS MUEHLER

Executive Officer · New York, NY

PATRICK WALSH

Executive Officer · New York, NY

THORVALD NAGEL

Director · New York, NY

HELLA KOHLHOF

Executive Officer · New York, NY

GLENN WHALEY

Executive Officer · New York, NY

INDERPAL SINGH

Executive Officer · New York, NY

BARCLAY PHILLIPS

Director · New York, NY

JASON TARDIO

Executive Officer · New York, NY

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Leerink Partners LLCCRD 000039011 on BrokerCheck

Associated broker-dealer: None · BOSTON, MA · Soliciting in CA, CO, CT, DE, GA, IL, MA, NC, NY, TX

STIFEL, NICOLAUS & COMPANY, INCORPORATEDCRD 000000793 on BrokerCheck

Associated broker-dealer: None · ST. LOUIS, MO · Soliciting in CA, CO, CT, DE, GA, IL, MA, NC, NY, TX

GUGGENHEIM SECURITIES, LLCCRD 000040638 on BrokerCheck

Associated broker-dealer: None · NEW YORK, NY · Soliciting in CA, CO, CT, DE, GA, IL, MA, NC, NY, TX

WILLIAM BLAIR & COMPANY, LLCCRD 000001252 on BrokerCheck

Associated broker-dealer: None · CHICAGO, IL · Soliciting in CA, CO, CT, DE, GA, IL, MA, NC, NY, TX

LIFESCI CAPITAL LLCCRD 000168404 on BrokerCheck

Associated broker-dealer: None · NEW YORK, NY · Soliciting in CA, CO, CT, DE, GA, IL, MA, NC, NY, TX

B. RILEY SECURITIES, INC.CRD 000025027 on BrokerCheck

Associated broker-dealer: None · LOS ANGELES, CA · Soliciting in CA, CO, CT, DE, GA, IL, MA, NC, NY, TX

BROOKLINE CAPITAL MARKETS, A DIVISION OF ARCADIA SECURITIES, LLCCRD 000044656 on BrokerCheck

Associated broker-dealer: None · NEW YORK, NY · Soliciting in CA, CO, CT, DE, GA, IL, MA, NC, NY, TX

Questions About IMMUNIC, INC.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is IMMUNIC, INC.?

IMMUNIC, INC. is a Delaware corporation that filed a Form D with the SEC on March 4, 2026 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is IMMUNIC, INC. legit?

AltStreet does not rate legitimacy; it reports the public record. IMMUNIC, INC. filed a Form D with the SEC on March 4, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $200,000,000 sold to 43 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is IMMUNIC, INC. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that IMMUNIC, INC. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has IMMUNIC, INC. raised?

IMMUNIC, INC. reported $200,000,000 sold from 43 investors of a $200,000,000 total offering as of the Form D filed March 4, 2026.

Who can invest in IMMUNIC, INC.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in IMMUNIC, INC.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling IMMUNIC, INC. and how are they paid?

The Form D names Leerink Partners LLC (CRD 000039011), associated with None; STIFEL, NICOLAUS & COMPANY, INCORPORATED (CRD 000000793), associated with None; GUGGENHEIM SECURITIES, LLC (CRD 000040638), associated with None; WILLIAM BLAIR & COMPANY, LLC (CRD 000001252), associated with None and 3 others as recipients of sales compensation soliciting in CA, CO, CT, DE, GA, IL, MA, NC, NY, TX. Sales commissions are reported as $12,000,000 and finders' fees as $0. Form D allows these to be estimates.

Who is behind IMMUNIC, INC.?

The Form D lists 14 related persons: DANIEL VITT, executive officer, director; SIMONA SKERJANEC, director; DUANE NASH, director; TAMAR HOWSON, director; JOERG NEERMAN, director; RICHARD RUDICK, director; ANDREAS MUEHLER, executive officer; PATRICK WALSH, executive officer, and 6 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is IMMUNIC, INC. located?

The issuer's address on its SEC filings is 1200 Avenue of the Americas, Suite 200, New York, United States 10036. Its phone number of record is (332) 255-9818. It is organized under the laws of Delaware.

How long is the IMMUNIC, INC. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 2 amendments are on record for this CIK.

What is IMMUNIC, INC.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.